Investigation into the Bronchoprotective and Anti-inflammatory Properties of RGS2

Simple item page
atmire.migration.oldid4881
dc.contributor.advisorNewton, Robert
dc.contributor.authorGeorge, Tresa
dc.contributor.committeememberGiembycz, Mark
dc.contributor.committeememberKelly, Margaret
dc.date.accessioned2016-09-09T22:06:42Z
dc.date.available2016-09-09T22:06:42Z
dc.date.issued2016
dc.date.submitted2016en
dc.description.abstractThe clinical management of asthma involves treatment with inhaled corticosteroids (ICS) and long-acting β2-adrenoceptor agonists (LABAs). Regulator of G-protein signalling (RGS) 2 inhibits signalling from Gq protein-coupled receptors. In humans, combinations of a glucocorticoid and a LABA synergistically enhanced the expression of RGS2. In mice, 3 weeks of HDM challenge or 30 min of LPS challenge reduced lung function and induced airways inflammation. Compared to wild-type, Rgs2-/- mice showed significantly increased airways resistance and reduced compliance, in both HDM- and LPS-challenges. There was no difference between wild-type and Rgs2-/- mice in HDM-induced and LPS-induced inflammation. There was a trend towards increased inflammatory cell counts in the BALF of Rgs2-/- compared to wild-type. There was a trend towards increased expression for many HDM-induced cytokines/chemokines in Rgs2-/-. There was no difference between wild-type and Rgs2-/- mice in LPS-induced expression of cytokines/chemokines. These data show Rgs2 is bronchoprotective in HDM-induced inflammation and suggest a modest anti-inflammatory role. Rgs2 is bronchoprotective in LPS-induced inflammation, but more studies are required to address a possible anti-inflammatory role. If applicable to humans, these data suggest that therapeutics, for example ICS/LABA combination therapies, which are designed to maximize RGS2 expression, will be beneficial for asthma control and management.en_US
dc.identifier.citationGeorge, T. (2016). Investigation into the Bronchoprotective and Anti-inflammatory Properties of RGS2 (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/26649en_US
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/26649
dc.identifier.urihttp://hdl.handle.net/11023/3283
dc.language.isoeng
dc.publisher.facultyCumming School of Medicine
dc.publisher.facultyGraduate Studies
dc.publisher.institutionUniversity of Calgaryen
dc.publisher.placeCalgaryen
dc.rightsUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.
dc.subjectGenetics
dc.subjectBiology--Molecular
dc.subjectPharmacology
dc.subjectBiochemistry
dc.subject.classificationAsthmaen_US
dc.subject.classificationAllergyen_US
dc.subject.classificationMiceen_US
dc.subject.classificationHDMen_US
dc.subject.classificationLPSen_US
dc.subject.classificationRGS2en_US
dc.titleInvestigation into the Bronchoprotective and Anti-inflammatory Properties of RGS2
dc.typemaster thesis
thesis.degree.disciplineCardiovascular & Respiratory Sciences
thesis.degree.grantorUniversity of Calgary
thesis.degree.nameMaster of Science (MSc)
ucalgary.item.requestcopytrue
Files
Collections
Open Theses and Dissertations